Skip to content

Cryotherapeutics

Active
Public limited companyfounded 2018active for 7 yearsAvenue Alfred Deponthière 46, 4431 Ans, BelgiumKBO/BCE: BE 0713.882.584
Summary

Cryotherapeutics has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €21.1m and a net result of -€2.3m. Equity is growing by about 3% per year across the filed financial years. Its solvency ranks better than 95% of 88 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).

Overview

Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21209Other research and development on natural sciences NACE 72109
#3 company by total assets in Ans, Manufacturing sector1 site
Size
€21.8mtotal assets 2025
Staff
10.7 FTE
Equity
€21.1m
Loss
-€2.3m
Financial health
84 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.5%
Structure
Holdings
1
Accounts 60 days early2 of 14 deeds read
Why 84raises riskLoss of €2.3m, the second in a row (financial year 2025)1 change of registered office in 24 monthslowers riskFigures for financial year 2025 (filed 03-06-2026)Liquidity: current ratio 7.27, cash €2.8mShow the evidence

Checked score

Score 2025
84 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 58% of its sector peers (NACE 21, small)
Financial strength · tick = 2024
Average
Solvency 100=
equity 96.8% of total assets
Liquidity 66=
short-term debt 3.2% · cash 12.8%
Profitability 6-3
return on assets -10.4%
Bankruptcy probability, 12 months
0.5% Very low
0%0.5%1.5%4%10%≥ 25%

About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.5% (43 companies, NACE 21, small)
Last 24 months 11-2024: 0.5% 12-2024: 0.5%● unchanged vs 11-2024 01-2025: 0.5%● unchanged vs 12-2024 02-2025: 0.5%● unchanged vs 01-2025 03-2025: 0.5%● unchanged vs 02-2025 04-2025: 0.6%▲ +0.1 percentage points vs 03-2025 05-2025: 0.6%● unchanged vs 04-2025 06-2025: 0.7%▲ +0.1 percentage points vs 05-2025highest value 07-2025: 0.2%▼ -0.5 percentage points vs 06-2025lowest value 08-2025: 0.2%● unchanged vs 07-2025lowest value 09-2025: 0.2%● unchanged vs 08-2025lowest value 10-2025: 0.2%● unchanged vs 09-2025lowest value 11-2025: 0.3%▲ +0.1 percentage points vs 10-2025 12-2025: 0.3%● unchanged vs 11-2025 01-2026: 0.3%● unchanged vs 12-2025 02-2026: 0.3%● unchanged vs 01-2026 03-2026: 0.3%● unchanged vs 02-2026 04-2026: 0.4%▲ +0.1 percentage points vs 03-2026 05-2026: 0.5%▲ +0.1 percentage points vs 04-2026 06-2026: 0.5%● unchanged vs 05-2026 07-2026: 0.5%● unchanged vs 06-2026 08-2026: 0.5%● unchanged vs 07-2026 09-2026: 0.5%● unchanged vs 08-2026 10-2026: 0.5%● unchanged vs 09-2026
Credit of up to €1,750,000 on 30-day terms is acceptable
Liquidity ample (current ratio 7.27, compared with 5.76 in 2024; short-term debt: 3.2% and cash: 12.8% of total assets), and 3.2% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, small): better than 88% on solvency, 86% on liquidity, 28% on profitability and 30% on growth.

The bankruptcy probability was computed on 08-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
−lowers risk+raises risk○neutral
raises risk · Loss of €2.3m, the second in a row (financial year 2025)
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
lowers risk · Figures for financial year 2025 (filed 03-06-2026)
NBB · annual accounts
lowers risk · Liquidity: current ratio 7.27, cash €2.8m
NBB · annual accounts
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025
Net result per financial year
19202122232425
2019 to 2025 · latest year -€2.3m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 01-06-2026, 60 days ahead of the deadline.
NBB · 7 filings
Deviation from the deadline
2025
60 days early
2024
42 days early
2023
54 days early
2022
16 days early
2021
11 days early
2020
22 days early
2019
95 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 16 days before the deadline; the sector median (NACE 21) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 19 June (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
09-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Capital & shares · Amendment of…Share class · Financial instrument…
  3. Weakest financial yearnet -€2.3m

Key points

  • Risk: 7 loss-making years in a rowloss financial year 2025 -€2.3m View
  • Caution: Among the weakest 10% on net resultsector median €354,226 · 88 companies -€2.3m View
  • Positive: Filed on time since financial year 2020accounts within the deadline every year 6 years View

By topic

Financials

Financial year
2025
Total assets
€21.8m
Loss
-€2.3m
Solvency
96.8%
Total assets▼ 12.0%
Net result
20192025
Go to Financials

Timeline

Events
12
Since
2020
Next accounts
by 31-07-2027
  1. 21-10-2025Registered office
  2. 19-06-2025Annual accounts filed
  3. 31-12-2024Liquidity more than triples
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21209
Founded
26-11-2018
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
22
Annual meeting
First Tuesday of May at 11:00
Purpose
Le développement et la commercialisation de produits médicaux utilisant la cryothérapie
Go to Articles of association

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.